Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 12
Submit an article Journal homepage
4,365
Views
6
CrossRef citations to date
0
Altmetric
Respiratory Medicine

Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK

Omendra Narayana Royal Manchester Children’s Hospital, Manchester, UK;b Paediatric Respiratory Medicine, University of Manchester, Manchester, UK
,
Anthony Bentleyc Mtech Access Limited, Bicester, UK
,
Katie Mowbrayd AbbVie Limited, Maidenhead, UK
,
Monika Hermanssond AbbVie Limited, Maidenhead, UK
,
Dominic Pivonkad AbbVie Limited, Maidenhead, UK
,
Eric Ngonga Kemadjoue JB Medical Limited, Sudbury, UKCorrespondence[email protected]
&
Jonathan Belseye JB Medical Limited, Sudbury, UK
 show all
Pages 1640-1652 | Received 06 Aug 2020, Accepted 05 Oct 2020, Published online: 27 Oct 2020

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Barry S. Rodgers-Gray, John R. Fullarton, Xavier Carbonell-Estrany, Ian P. Keary, Jean-Éric Tarride & Bosco A. Paes. (2023) Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of Medical Economics 26:1, pages 630-643.
Read now
Gemechu Churiso, Gose Husen, Denebo Bulbula & Lulu Abebe. (2022) Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors: A Systematic Review. Infection and Drug Resistance 15, pages 7413-7430.
Read now

Articles from other publishers (4)

Ian P. Keary, Roberto Ravasio, John R. Fullarton, Paolo Manzoni, Marcello Lanari, Bosco A. Paes, Xavier Carbonell-Estrany, Eugenio Baraldi, Jean-Éric Tarride & Barry Rodgers-Gray. (2023) A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age. PLOS ONE 18:8, pages e0289828.
Crossref
Christina Ebersjö, Eva Berggren Broström, Inger Kull & Anna Lindholm Olinder. (2023) Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences. Children 10:2, pages 198.
Crossref
Margaret Gilfillan, Anita Bhandari & Vineet Bhandari. (2021) Diagnosis and management of bronchopulmonary dysplasia. BMJ, pages n1974.
Crossref
Alessandro Rocca, Carlotta Biagi, Sara Scarpini, Arianna Dondi, Silvia Vandini, Luca Pierantoni & Marcello Lanari. (2021) Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?. International Journal of Molecular Sciences 22:7, pages 3703.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.